This post was originally published on this site
In January, when Daniel O’Day had been chief executive of Gilead Sciences for not quite a year, his researchers told him about an experimental medicine called remdesivir, which might prove useful against the latest coronavirus outbreak. “It wasn’t an …
Click here to read full article